CGON News and Press, CG Oncology, Inc. From 01/11/26

2026-01-11 08:30:11 ET The last time I spoke about CG Oncology ( CGON ) it was with respect to a Seeking Alpha article entitled " CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene ". With respect to this article, I noted that the company had achieved ...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 9.3% to $2.33 on volume of 358,015,602 shares Mingteng International Corporation Inc. (MTEN) fell 78.9% to $0.1271 on volume of 279,036,858 shares RenX Enterprises Corp. (RENX) ros...

2026-01-09 13:33:21 ET More on CG Oncology CG Oncology Undervalued Going Into A Busy 2026 ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves ClearBridge SMID Cap Growth Strategy adds CRDO, RKLB, exits OSCR, RARE Seeking Alpha’...

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09,...

IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairm...

2025-12-26 16:00:35 ET Shares of bladder cancer gene therapy concern enGene Holdings Inc. ( ENGN ) rallied over 50% after providing data from its protocol-revised pivotal cohort of a Phase 2 trial on November 10, 2025. The results were encouraging with a 62% CR rate at six m...

2025-12-23 13:26:50 ET More on Abivax, Revolution Medicines, etc. Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026 Janux Therapeutics, Inc. (JANX) Shareho...

2025-12-23 04:43:51 ET Biotech stocks may generally be data-driven, but that doesn’t mean that the share prices always reflect the value that the data imply. Such is the case with CG Oncology, Inc. ( CGON ), where the company’s data releases since my last update on the...

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Applications for the fellowship are due on February 27, 2026 SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Th...

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and favorable safety with optimized administration Robust...